StemCell Institute (7096) AI Stock Analysis

• Market Cap: ¥9.63B
• Dividend Yield: N/A
• Average Volume (3M): 43.66K
• Price to Earnings (P/E): 38.4
• Beta (1Y): 0.38
• Revenue Growth: 4.58%
• EPS Growth: -39.30%
• Country: JP
• Employees: 98
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 4.24
• Shares Outstanding: 10,246,600
• 10 Day Avg. Volume: 25,000
• 30 Day Avg. Volume: 43,656
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥1,115.00
• Price Target Upside: 18.62% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 70 Outperform
• Price Target: ¥1,115.00 ▲(18.62% Upside)

StemCell Institute's strong financial performance, particularly in revenue growth and profitability, is the primary driver of its stock score. However, technical indicators suggest a neutral market sentiment, and the high P/E ratio indicates potential overvaluation, which tempers the overall score.

StemCell Institute Business Overview & Revenue Model

Company Description

StemCell Institute (7096) is a biotechnology company specializing in the research and development of stem cell therapies. The company operates within the healthcare sector, focusing on regenerative medicine and cellular treatments to address a variety of medical conditions. Its core services include conducting clinical trials, developing innovative stem cell-based products, and providing stem cell banking services.

How the Company Makes Money

StemCell Institute generates revenue primarily through the development and commercialization of stem cell therapies. The company earns money by partnering with healthcare providers and pharmaceutical companies to co-develop and distribute its products. Additional revenue streams include fees from clinical trials conducted for new treatments, as well as payments for stem cell banking services offered to individuals and medical institutions. Significant partnerships with research organizations and hospitals further enhance its earnings potential by expanding its reach and facilitating new product development.

StemCell Institute Financial Statement Overview

Summary

StemCell Institute exhibits strong revenue growth and profitability, supported by robust margins and a solid capital structure. However, the negative free cash flow warrants attention, indicating a need for better cash management.

Income Statement

StemCell Institute shows strong revenue growth with a 7.97% increase from the previous year. The gross profit margin is robust at 63.16%, and the net profit margin has improved to 14.40%, indicating efficient cost management and profitability. The EBIT and EBITDA margins of 15.62% and 25.94% respectively, reflect solid operational efficiency.

Balance Sheet

The company maintains a healthy balance sheet with a low debt-to-equity ratio of 0.20, showcasing financial stability. The equity ratio of 35.02% suggests a strong capital structure. However, the return on equity is moderate at 14.68%, indicating potential for improved profitability.

Cash Flow

Operating cash flow to net income ratio is strong at 1.21, indicating good cash generation relative to net income. However, the free cash flow has turned negative, indicating potential challenges in cash management. The decrease in free cash flow from the previous year is a concern, suggesting a need for better capital expenditure management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.68B	2.68B	2.48B	2.09B	1.78B	1.41B
Gross Profit	1.69B	1.69B	1.58B	1.34B	1.11B	924.21M
EBITDA	553.35M	695.19M	534.00M	402.49M	309.47M	119.66M
Net Income	384.86M	385.80M	310.98M	198.03M	133.73M	62.37M
Balance Sheet
Total Assets	7.50B	7.50B	6.54B	5.81B	5.22B	3.96B
Cash, Cash Equivalents and Short-Term Investments	3.20B	3.20B	2.85B	3.32B	3.51B	2.74B
Total Debt	518.96M	518.96M	8.78M	5.89M	0.00	0.00
Total Liabilities	4.87B	4.87B	3.85B	3.51B	3.11B	2.64B
Stockholders Equity	2.63B	2.63B	2.69B	2.30B	2.10B	1.32B
Cash Flow
Free Cash Flow	0.00	-10.11M	132.97M	39.77M	264.81M	-164.34M
Operating Cash Flow	0.00	467.69M	334.63M	99.67M	469.29M	239.00M
Investing Cash Flow	0.00	-259.08M	-811.77M	-285.10M	404.17M	-520.26M
Financing Cash Flow	0.00	146.70M	-1.33M	-869.00K	644.37M	0.00

StemCell Institute Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 940.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7096, the sentiment is Negative. The current price of 940 is below the 20-day moving average (MA) of 946.10, below the 50-day MA of 990.64, and below the 200-day MA of 1191.98, indicating a bearish trend. The MACD of -15.65 indicates Negative momentum. The RSI at 43.30 is Neutral, neither overbought nor oversold. The STOCH value of 35.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7096.

StemCell Institute Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7096	70 Outperform	¥9.63B	38.36	―	―	4.58%	-39.30%
4880	66 Neutral	¥11.48B	-229.22	3.94%	0.86%	-13.81%	-107.95%
7774	58 Neutral	¥20.71B	-72.28	―	―	6.33%	-250.29%
7776	51 Neutral	¥15.77B	-15.22	-39.75%	―	-22.81%	2.69%
4978	49 Neutral	¥19.05B	-151.53	―	―	13.83%	34.66%
4599	47 Neutral	¥18.83B	-9.73	―	―	―	5.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

StemCell Institute Corporate Events

StemCell Institute Expands into Southeast Asia with Joint Venture

StemCell Institute Inc. has entered a joint venture with BIG RAINBOW INVESTMENT PTE. LTD., the family office of Sinar Mas Group, to expand its cell banking business in Southeast Asia. This strategic partnership aims to leverage StemCell’s expertise and the local networks of Sinar Mas Group to strengthen its presence and achieve sustainable growth in the region, with plans to explore related regenerative medicine services.